Table 2.
Self-reported 7-Day Point Prevalence Abstinence and 6-Week Continuous Abstinence Rates, by Group at 6- and 12-Week Follow-up Time Points
| 6-Week outcomes | |||||
|---|---|---|---|---|---|
| NVP | NRT | OR1 | 95% CI | p | |
| Self-reported 7-day point prevalence abstinence | |||||
| Complete cases Penalized imputation |
5/34 (15%) 5/50 (10%) |
7/29 (24%) 7/50 (14%) |
0.59 0.71 |
0.13–2.66 0.17–2.93 |
0.479 0.636 |
| Self-reported 6-week continuous abstinence | |||||
| Complete cases Penalized imputation |
8/34 (24%) 8/50 (16%) |
12/29 (41%) 12/50 (24%) |
0.43 0.59 |
0.11–1.66 0.18–1.97 |
0.212 0.388 |
| 12-Week outcomes | |||||
| NVP | NRT | OR1 | 95% CI | p | |
| Self-reported 7-day point prevalence abstinence | |||||
| Complete cases Penalized imputation |
7/25 (28%) 7/50 (14%) |
9/25 (36%) 9/50 (18%) |
0.75 0.76 |
0.17–3.27 0.21–2.73 |
0.696 0.676 |
| Self-reported 6-week continuous abstinence | |||||
| Complete cases Penalized imputation |
9/25 (36%) 9/50 (18%) |
10/25 (40%) 10/50 (20%) |
0.89 0.91 |
0.21–3.81 0.27–3.03 |
0.876 0.872 |
1Calculated from crude logistic mixed effect models (NRT = reference group).